INTRODUCTION
============

Vitamin D is a fat-soluble vitamin that is synthesized in the skin in response to sunlight exposure (as provitamin D3 and previtamin D3) and is also obtained, to a limited extent, from dietary intake (vitamins D2 and D3). Vitamin D is stored in adipose cells or is converted in the liver to its circulating form, 25-hydroxyvitamin D3 \[25(OH)D3\]. Mainly in the kidneys, 25(OH)D is converted to its active metabolite, 1,25-dihydroxyvitamin D \[1,25(OH)2D\], also known as calcitriol. Calcitriol synthesis is enhanced by parathyroid hormone (PTH) and hypophosphatemia. The endocrine action of calcitriol on bone mineral metabolism has been known for decades, and vitamin D supplementation has been advocated in patients with chronic conditions, such as osteoporosis. For many years, vitamin D deficiency was recognized as a chronic condition associated with bone pain, weakness and fractures in the general population. Serum vitamin D levels below 10 ng/mL (generally described as deficiency or severe deficiency) are associated with osteomalacia and rickets, whereas levels in the 20-30 ng/mL range (vitamin D insufficiency or subclinical deficiency) are associated with osteoporosis and elevated PTH and have the potential to cause long-term harmful effects on bone metabolism. Children with rickets are more susceptible to infections, and vitamin D has been implicated in the pathogenesis of tuberculosis [@b1-cln_70p326][@b2-cln_70p326][@b3-cln_70p326][@b4-cln_70p326]. The paracrine and autocrine effects of vitamin D have been increasingly reported in the literature. In recent years, it has become clear that several cell lines, including macrophages and cardiac muscle cells, express vitamin D receptors and the enzyme 25(OH)D3-1-alpha-hydroxylase, which allows the cells to convert 25(OH)D to its active form, 1,25(OH)2D [@b5-cln_70p326].

Studies have shown correlations between low vitamin D levels and certain cancers, immune system dysfunction, diabetes, cardiovascular disease, hypertension and metabolic syndrome [@b6-cln_70p326][@b7-cln_70p326][@b8-cln_70p326]. Thus, investigators in several fields, including critical care medicine, have turned their attention to the nonskeletal effects of vitamin D [@b9-cln_70p326][@b15-cln_70p326]. Some observational studies have demonstrated a high prevalence of vitamin D deficiency in critically ill patients, who are generally deprived of sunlight, confined to bed and fed diets with low vitamin D content.

Data regarding the association between vitamin D deficiency and poor ICU outcomes, such as mortality, increased length of stay, increased length of mechanical ventilation, and infections, are conflicting. After an initial report by Lee et al. [@b16-cln_70p326] suggesting a high prevalence of vitamin D deficiency in critically ill patients, a retrospective study involving 2,399 patients [@b14-cln_70p326] showed an association between vitamin D deficiency, mortality and positive blood cultures. Subsequently, smaller prospective studies did not find this association. Differences in the definition of vitamin D deficiency, the studied populations (surgical ICUs *versus* medical ICUs), the methodology of vitamin D measurement, the interventions not measured (such as the volume and type of solutions infused) and the geographical location may account for the different findings in these studies [@b17-cln_70p326][@b18-cln_70p326][@b24-cln_70p326]. The relevance of vitamin D measurement and kinetics at ICU admission is open to debate. Furthermore, the 25(OH)D levels required for proper maintenance of the pleiotropic effects of vitamin D remain unknown.

The purpose of this study was to assess the relationship between serum vitamin D levels at admission, vitamin D kinetics during ICU stay, and morbidity and mortality in critically ill patients.

MATERIALS AND METHODS
=====================

Study design and setting
------------------------

This is a prospective study of patients admitted to the medical-surgical ICU of a university hospital (Hospital de Clínicas de Porto Alegre, state of Rio Grande do Sul, Brazil) between March and November 2012. The city of Porto Alegre is located in the South of Brazil at 30°05\'S. The study protocol was approved by the institutional research ethics committee, and written informed consent was provided by all patients or their surrogates.

Methods
-------

We included adult patients (age 18 years and older) with a predicted length of ICU stay greater than 3 days. We excluded patients with a length of pre-ICU hospital stay \>3 days, chronic renal failure requiring dialysis or pre admission creatinine \>2 mg/dL, a life expectancy of less than 24 hours, pregnancy, admission for cardiac or elective surgery, hyper- or hypoparathyroidism, and granulomatous diseases, such as tuberculosis or sarcoidosis.

Patient demographic and clinical data were recorded on ICU admission, including age, sex, comorbidities, current medications, ethnicity, reason for admission, season, APACHE II score, and body mass index (BMI) (Kg/m^2^). The SOFA score was calculated at ICU admission and at ICU discharge or death. Infections and cultures (blood, sputum, urine, ascites or pleural fluid) were prospectively assessed throughout the ICU stay for each patient. Patients were considered infected when the attending physicians, who were not involved with the study and had no access to serum 25(OH)D levels, diagnosed ICU-acquired infections and prescribed antimicrobials to their patients. In addition to the total number of positive cultures and clinically overt infections, the incidence rates of culture positivity and infection over time were also assessed. Patients were also assessed for the duration of mechanical ventilation, length of ICU stay, length of hospital stay, and 28-day mortality.

Biochemical analysis
--------------------

Blood samples were collected within 24 hours of ICU admission for the measurement of capillary blood glucose, PTH, ionized calcium, albumin, creatinine, phosphorus, magnesium, C-reactive protein, and lactate. The estimated glomerular filtration rate was calculated using the MDRD equation [@b10-cln_70p326]. All tests were performed by routine methods employed at the biochemistry laboratory of Hospital de Clínicas de Porto Alegre. 25(OH)D was measured once weekly for 4 weeks or until ICU discharge. Samples were protected from sunlight exposure, centrifuged and stored under refrigeration until processing, which was performed once weekly on Fridays. 25(OH)D levels were measured using the chemiluminescence method (Liaison; Diasorin, Stillmater, Minnesota; inter- and intra-assay coefficients of variation, 10%) and reported in ng/mL [@b11-cln_70p326]. (To convert the 25(OH)D concentration from ng/mL to nmol/L, multiply by 2.5.) PTH levels were measured by a chemiluminescent immunoassay (Advia Centaur XP; Siemens Healthcare Diagnostics Inc.).

Statistical analysis
--------------------

Normally distributed quantitative variables are expressed as the mean ± standard deviation. Asymmetrically distributed variables are expressed as the median \[interquartile range\]. The chi-square test was used for the assessment of categorical variables, and Student's *t*-test was used for continuous variables. Normally distributed and asymmetric variables were compared using the Mann-Whitney *U* test. Receiver-operating characteristic (ROC) curves were plotted to illustrate 25(OH)D cutoff values. Relative risks (along with 95% confidence intervals) were estimated using Poisson regression adjusted for 6 covariates: lactate, albumin, SOFA and APACHE II scores, sepsis as the reason for ICU admission and BMI. Survival analysis was performed by means of Kaplan-Meier curves. Log-rank statistics were used to determine significant differences over time. For the comparative analysis of changes in the 25(OH)D levels over time during ICU admission between survivors and non-survivors, we used a generalized estimating equation model for longitudinal data analysis [@b12-cln_70p326]. Infection and culture positivity rates were compared by means of incidence density ratio analysis. The significance level was set at *p*\<0.05.

RESULTS
=======

Cohort profile
--------------

Overall, 135 patients were included. The 28-day mortality rate was 21.5%. Slightly less than half of all patients (47%) were women, and 78% were Caucasian. The median vitamin D level at admission was 13.3 \[8.1-20\] ng/mL. Only 16 patients (11.8%) were vitamin D sufficient (25(OH)D\>30 ng/mL); 101 (74.8%) were vitamin D insufficient (25(OH)D\<20 ng/mL). Five patients were on bisphosphonate, calcium, and vitamin D therapy prior to admission. These patients' 25(OH)D levels ranged from 4.7 ng/mL to 18 ng/mL. No patient received supplemental vitamin D during his or her ICU stays. The sample profile is shown in [Table 1](#t1-cln_70p326){ref-type="table"}. Non-survivors had higher APACHE II and SOFA scores and PTH and lactate levels on admission and had more difficult clinical courses with more organ dysfunction (lower ΔSOFA). In addition, fewer progressed to enteral feeding; five patients were never fed due to death secondary to refractory shock within the first few days of ICU admission. Electrolytes and renal function were assessed in 117 patients who were not on dialysis at the time of 25(OH)D measurement. Non-survivors had lower ionized calcium levels and lower glomerular filtration rates ([Table 2](#t2-cln_70p326){ref-type="table"}).

The area under the ROC curve for 25(OH)D levels at admission in relation to mortality was 0.61 (95%CI 0.49-0.73), similar to those for APACHE II (0.7, 95% CI 0.59-0.8) and SOFA scores (0.7, 95% CI 0.6-0.8). The best cutoff was 11.9 ng/mL, with a sensitivity of 65%, a specificity of 62%, a negative predictive value of 86.8%, and a positive predictive value of 32.2% ([Figure 1](#f1-cln_70p326){ref-type="fig"}).

Compared with patients with 25(OH)D levels \>12 ng/mL, the 59 patients with 25(OH)D≤12 ng/mL (43.7% of the sample) had higher prevalence rates of prior corticosteroid therapy (18% *vs.* 2.6%; *p*=0.005) and of acute respiratory failure as a reason for ICU admission (25% *vs.* 6.6%; *p*=0.013). Although there is no difference between the median vitamin D levels among seasons, a seasonal association was found for the prevalence of vitamin D deficiency (*p*=0.041), which was more common in the winter (37.3% *vs.* 21%) and less common in the summer (10.2% *vs.* 27.6%). Vitamin D-deficient patients had higher BMIs (27.4 Kg/m^2^ \[24.2-35.2\] *vs.* 26 Kg/m^2^ \[22.7-29.3\]; *p*=0.015). There were no differences in APACHE II scores (19.8±9 *vs.* 18.7±8.3; *p*=0.482), SOFA scores at admission (5 \[2-8\] *vs.* 5 \[3-8\]; *p*=0.170), albumin (3.08±0.78 g/dL *vs.* 3.06±0.6 g/dL; *p*=0.87), ionized calcium (4.7 \[4.4-5.0\] mg/dL *vs.* 4.7 \[4.5-4.8\] mg/dL; *p*=0.770), or PTH (146 \[79-260\] pg/mL *vs.* 107 \[53-200\]; *p*=0.70), which was elevated in both groups. Patients with 25(OH)D levels ≤12 ng/mL developed greater organ system dysfunction during their ICU stays (ΔSOFA: 0.9±4.7 *vs.* 3.4±3.9; *p*=0.001).

Mortality
---------

Over the course of the 28-day observation period, 19 of the 59 patients with 25(OH)D levels ≤12 ng/mL died (32.2%), compared with 10 of the 76 patients with 25(OH)D levels \>12 ng/mL (13.2%); this difference was statistically significant (*p*=0.014). The crude relative risk of death was 2.11 (95% CI 1.08-4.11). After multivariable adjustment, the relative risk remained significantly higher, at 2.20 (95% CI 1.07-4.54) ([Table 3](#t3-cln_70p326){ref-type="table"}).

There were no significant differences in mortality (23.5% *vs.* 15.2%; *p*=0.275) when the 25(OH)D cutoff was set at 20 ng/mL.

Length of stay
--------------

25(OH)D levels ≤12 ng/mL were not associated with any significant differences in the overall length of hospital stay (20 \[9-28\] *vs.* 23.5 \[14-28\], *p*=0.869) or length of ICU stay (9 \[5-21\] *vs.* 9 \[5-21\], *p*=0.092), in days.

Mechanical ventilation
----------------------

Invasive mechanical ventilation was used in 44 (74.6%) patients with 25(OH)D levels ≤12 ng/mL and in 59 (77.7%) patients with 25(OH)D levels \>12 ng/mL (*p*=0.834).

Infection and culture positivity
--------------------------------

Overall, 78 patients (57.8%) had positive cultures at some point during their ICU stays. Among the 59 patients with 25(OH)D≤12 ng/mL, a total of 73 infections and 101 positive cultures (including 28 positive blood cultures) were detected. Among the 76 patients with 25(OH)D\>12 ng/mL, 88 infections and 121 positive cultures (including 32 positive blood cultures) were detected. The rates of infection and culture positivity per 100 patient-days in the ICU are shown in [Table 4](#t4-cln_70p326){ref-type="table"}. There were no significant differences between groups for either indicator.

Vitamin D kinetics
------------------

A slight decrease in 25(OH)D concentrations occurred over time, reaching statistical significance only on day 21 among all patients. Among non-survivors, a non-significant decline in 25(OH)D levels occurred at the 14^th^ day of ICU stay. The decline in vitamin 25(OH)D levels through ICU stay were not related to mortality or other clinical outcomes.

DISCUSSION
==========

Our findings show that severe vitamin D deficiency is an independent predictor of mortality in critically ill patients. In this sample, a 25(OH)D level of 12 ng/mL was the best cutoff for the identification of critically ill patients at a higher risk of death.

The relationship between mortality and serum vitamin D levels in critically ill patients is a topic of debate in the current literature [@b13-cln_70p326]. While some studies have reported such an association [@b14-cln_70p326][@b15-cln_70p326][@b16-cln_70p326][@b17-cln_70p326][@b18-cln_70p326][@b19-cln_70p326][@b20-cln_70p326][@b21-cln_70p326], others have not [@b22-cln_70p326][@b23-cln_70p326][@b24-cln_70p326][@b25-cln_70p326][@b26-cln_70p326][@b27-cln_70p326]. The higher mortality rate among severely vitamin D-deficient subjects found in this study is in agreement with the retrospective studies of Braun et al [@b14-cln_70p326][@b15-cln_70p326]. Our study confirms these findings with a prospective design and also demonstrates that the increased mortality attributed to vitamin D deficiency persists even after adjusting the risk for variables associated with mortality. Notably, APACHE II and SOFA scores on admission were similar in 25(OH)D-deficient and non-deficient patients. Nevertheless, the mortality rate was higher in the 25(OH)D-deficient group. In 2012, Higgins et al. [@b24-cln_70p326] conducted a prospective study and found no significant differences in mortality among critically ill vitamin D-deficient patients, although deficient patients had longer ICU lengths of stay. The authors note that their study was not powered to detect differences in mortality. Heterogeneity between studies may explain the different results. The Higgins et al sample was older, and data collection occurred between 2002 and 2003 in Canada, while our data collection occurred in 2012 in Southern Brazil. In our study, we excluded patients with a total length of hospital stay \>3 days before ICU transfer, whereas Higgins et al had no such exclusion criterion. We thus excluded patients with normal pre-admission vitamin D levels whose decrease in serum 25(OH)D levels was attributable to hospitalization. Our sample had a higher prevalence of sepsis as the reason for ICU admission. Some studies have suggested that this etiology may be associated with higher mortality related to vitamin D deficiency [@b6-cln_70p326].

Vitamin D may be no more than a marker of severity in critically ill patients. However, the literature reports several vitamin D-dependent physiological mechanisms, suggesting that 25(OH)D deficiency may be implicated in the pathogenesis of organ dysfunction and mortality in critically ill patients, perhaps mediated by its effects on immunity and on the cardiovascular system [@b6-cln_70p326][@b9-cln_70p326][@b27-cln_70p326]. As ours was an observational study, we cannot ascertain whether the association between vitamin D deficiency and mortality is causal or attributable to chance. However, even after logistic regression, 25(OH)D levels \<12 ng/mL remained an independent predictor of mortality.

The current literature provides no information on the 25(OH)D level that can adequately support the pleiotropic effects of vitamin D. In our population, ROC curve analysis identified 12 ng/mL as the best cutoff for mortality. This finding is similar to that reported in a retrospective study [@b18-cln_70p326]. Even if 25(OH)D is merely a marker of severity, these studies suggest that vitamin D levels \<10-12 ng/mL can be used to identify patients at a higher risk of mortality and can prompt more intensive monitoring of these patients. In non-critically ill patients, 25(OH)D levels this low are incapable of maintaining serum concentrations of 1,25(OH)2D, leading to clinical repercussions such as rickets and osteomalacia. This study suggests that, similarly to outpatients, critically ill patients with severe vitamin D deficiency suffer the most clinical consequences from the lack of vitamin D; from this finding, we infer that these patients are most likely to benefit from vitamin D replacement during the ICU stay. This hypothesis must still be confirmed by clinical trials. Dietary vitamin D intake is reduced in critically ill patients. Enteral formulas provide 200 to 300 IU/1000 mL, as do multivitamins. The current recommended daily intake of 200 IU/day is not enough to restore vitamin D to a sufficient level [@b30-cln_70p326]. Two recent studies showed that higher (yet safe) doses are required for vitamin D replacement in critically ill patients [@b31-cln_70p326][@b32-cln_70p326]. Our results also align with those of a recently published clinical trial [@b33-cln_70p326]. In this trial, patients randomized to the intervention group received a loading dose of 540,000 IU of vitamin D followed by 90,000 IU monthly for 5 months. The analysis of the subgroup of patients with baseline levels of vitamin D \<10 ng/mL showed a decrease in mortality. This result requires confirmation in future multicenter randomized clinical trials before a therapeutic recommendation can be generated.

As in other prospective studies [@b24-cln_70p326][@b34-cln_70p326], we found no significant differences in infection and culture positivity rates between vitamin D-deficient and non-deficient patients. Previous studies have shown a trend toward a greater incidence of infections but have lacked the statistical power to conclusively establish this association. Higher rates of infection and culture positivity have been observed among vitamin D-deficient patients in retrospective studies [@b14-cln_70p326], which, despite design bias, are able to include larger samples.

Although the literature suggests an association between 25(OH)D deficiency and morbidity in critically ill patients, our study did not find a longer duration of mechanical ventilation among patients with severe vitamin D deficiency. These results are consistent with other recently published prospective studies conducted in critically ill adult [@b17-cln_70p326][@b18-cln_70p326][@b21-cln_70p326] and pediatric [@b26-cln_70p326] populations.

In this study, we observed a modest decrease in 25(OH)D levels in critically ill patients, with a tendency toward lower levels among non-survivors. Only two other studies have prospectively measured vitamin D levels during the course of an ICU stay [@b24-cln_70p326][@b28-cln_70p326]. In both studies, data collection was restricted to 7 and 10 days of hospitalization. In our study, we measured 25(OH)D levels once weekly until the 28^th^ day in the ICU and found that non-survivors may have experienced a greater decrease in 25(OH)D concentrations after the second week in the ICU. As the half-life of 25(OH)D is approximately 15 days, these findings partly reflect the lack of vitamin D intake during the ICU stay due to a lack of sunlight exposure and low vitamin D concentrations in the diet provided to critically ill patients. Prior studies have shown a decrease in vitamin D-binding protein (VDBP) concentrations during an ICU stay [@b29-cln_70p326], corroborating the decline in 25(OH)D levels during admission, particularly in non-survivors. This behavior is analogous to that observed with other constitutional proteins, the synthesis of which is inhibited as metabolic pathways shift to the production of acute phase proteins in the setting of systemic inflammatory response syndrome (SIRS). Therefore, the criticality of the illness may also be reflected by serum vitamin D levels.

The high prevalence of vitamin D deficiency and insufficiency observed in our sample is consistent with other studies carried out at other centers, as well as with the high prevalence found in the non-critically ill population in our center [@b35-cln_70p326]. We are unaware of other reports of the prevalence and incidence of vitamin D deficiency in critically ill patients in South and Central America.

This study has some limitations. It was conducted at a tertiary care center with a largely Caucasian population and a relatively small sample size. The infection rate was solely calculated based on clinical diagnoses made by the assisting physicians. We cannot completely rule out the potential influence of unassessed variables---such as the volume infused in the first hours after admission or the cause of death---on mortality [@b36-cln_70p326]. Vitamin D measurements were not performed in duplicate. VDBP and biologically active 25(OH)D metabolites were not measured. Notably, albumin levels did not differ according to the vitamin D status. Importantly, the pleiotropic effects of vitamin D are dependent on local vitamin D concentrations; it is biologically plausible that these effects would be independent of serum 25(OH)D levels. Furthermore, the association between mortality and severe vitamin D deficiency found in this observational study is not enough to recommend the measurement of vitamin D levels in critically ill patients or supplementation in those with vitamin D deficiency; such changes in practice would depend on the results of clinical trials, which are ongoing.

The strengths of this study include its assessment of a hard endpoint (mortality) that is not prone to measurement bias. In addition to 25(OH)D levels, we measured other components that affect the vitamin D axis such as PTH, ionized calcium, magnesium, and phosphorus. The method employed for 25(OH)D measurement was the DiaSorin radioimmunoassay, which is currently considered the standard for this purpose in view of its excellent agreement with isotope dilution liquid chromatography-tandem mass spectroscopy (LC-MS) [@b13-cln_70p326][@b37-cln_70p326].

In our study, PTH levels were higher among non-survivors. The elevation of PTH among critically ill patients is due to factors such as peripheral resistance to the action of PTH, especially in the acute phase, in hypovitaminosis D and in hypocalcemia, and may be related to morbidity in critically ill patients [@b38-cln_70p326]. Thus, PTH itself appears to be a marker of severity, as observed with TSH or cortisol; however, PTH does not appear to be a potential therapeutic target, unlike vitamin D.

This study found that low vitamin D levels on admission are an independent risk factor for mortality in critically ill patients. The best cutoff of 25(OH)D levels on admission for stratifying the risk of death among critically ill patients was 12 ng/mL. As well as being markers of disease severity, low vitamin D levels and vitamin D kinetics during ICU admission may be causally associated with mortality and may serve as indicators for vitamin D supplementation in this patient population. Nevertheless, randomized trials are required to confirm this hypothesis.
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###### Sample profile.

                                         **Survivors (n=106)**    **Non-survivors (n=29)**   *p-***value**
  ------------------------------------- ------------------------ -------------------------- ---------------
  **Age, years**                               55.4±16.1                 60.4±16.6               0.141
  **Gender, n (%)**                                                                         
  Female                                        48 (45%)                  16 (55%)               0.462
  Male                                          58 (55%)                  13 (45%)          
  **Comorbidities, n (%)**                                                                  
  Coronary artery disease                      12 (11.3%)                 3 (10%)                0.882
  Hypertension                                  54 (51%)                  14 (48%)               0.964
  Heart failure                                 13 (12%)                  3 (10%)                1.000
  Diabetes                                      27 (25%)                  6 (21%)                0.774
  Hypothyroidism                                3 (2.8%)                  3 (10%)                0.113
  Chronic renal failure                         3 (2.8%)                  1 (3.4%)               1.000
  COPD                                          19 (18%)                  5 (17%)                1.000
  Asthma                                        4 (3.8%)                  3 (10%)                0.169
  AIDS                                          8 (7.5%)                     0                   0.201
  Cirrhosis                                     9 (8.5%)                  3 (10%)                0.720
  Stroke                                        7 (6.6%)                  4 (14%)                0.249
  Depression                                    8 (7.5%)                     0                   0.201
  Neoplasia                                     14 (13%)                 5 (17.2%)               0.557
  Other                                         20 (19%)                  7 (24%)                0.714
  **Chronic medications, n (%)**                                                            
  Diuretic                                     28 (26.4%)                 11 (38%)               0.326
  Corticosteroid                                8 (7.5%)                  5 (17%)                0.125
  Ca/VITD                                       3 (2.8%)                   2 (7%)                0.292
  Bisphosphonate                                 1 (1%)                   1 (3.4%)               0.385
  Antiepileptic                                 4 (3.8%)                 3 (10.3%)               0.169
  Proton pump inhibitor                        10 (9.4%)                  1 (3.4%)               0.456
  **Ethnicity, n (%)**                                                                           0.660
  Caucasian                                    83 (78.3%)                22 (75.9%)         
  African                                      14 (13.2%)                3 (10.3%)          
  Other                                         9 (8.5%)                 4 (13.8%)          
  **Reason for ICU admission, n (%)**                                                            0.009
  Sepsis                                        34 (32%)                  14 (48%)          
  Acute respiratory failure                     17 (16%)                  3 (10%)           
  Post-surgery                                  5 (4.7%)                  1 (3.4%)          
  Post-cardiac arrest                           4 (3.8%)                  1 (3.4%)          
  Coma                                          4 (3.8%)                 5 (17%)\*          
  Non-septic shock                              4 (3.8%)                  3 (10%)           
  Acute renal failure                           4 (3.8%)                     0              
  Other                                        34 (32%)\*                  2 (7%)           
  **Provenance, n (%)**                                                                          0.839
  Emergency department                          73 (69%)                  21 (72%)          
  Ward                                          2 (1.9%)                     0              
  Operating theater                             11 (10%)                   2 (7%)           
  Other                                         20 (30%)                 6 (20.7%)          
  **Admission service, n (%)**                                                                   0.924
  Medical                                       80 (75%)                  21 (72%)          
  Surgical                                      26 (25%)                  8 (28%)           
  **Season of admission, n (%)**                                                                 0.577
  Summer                                        23 (22%)                  4 (14%)           
  Autumn                                        36 (34%)                 8 (27.5%)          
  Winter                                        28 (26%)                 10 (34.5%)         
  Spring                                        19 (18%)                  7 (24%)           
  **APACHE II score**                       17 \[12 to 23\]           23 \[18 to 29\]            0.001
  **SOFA score**                             4.5 \[2 to 8\]           7 \[4.5 to 12\]            0.001
  **ΔSOFA**                                  3.0 \[1 to 6\]          −2 \[−5.5 to 1.5\]          0.001
  **BMI (Kg/m^2^)**                      26.7 \[23.3 to 30.5\]     26.5 \[23.5 to 31.6\]         0.823
  **Capillary blood glucose (mg/dL)**      146 \[113 to 193\]        141 \[99 to 189\]           0.485
  **Albumin (g/dL)**                            3.1±0.6                   2.7±0.8                0.004
  **CRP (mg/L)**                            83 \[28 to 231\]         168 \[23 to 264\]           0.316
  **Lactate (mmol/L)**                      1.4 \[1 to 2.1\]         3.1 \[1.4 to 5.6\]          0.001
  **PTH (pg/mL)**                        97.9 \[56.8 to 198.6\]    200.8 \[92.6 to 331\]         0.023

COPD, chronic obstructive pulmonary disease; Ca/VITD: calcium/vitamin D ratio; ΔSOFA, SOFA on admission - final SOFA (at ICU discharge or death); BMI, body mass index (Kg/m^2^); CRP, C-reactive protein; PTH, parathyroid hormone. \* denotes a statistically significant change. Summer: December 21 to March 21. Autumn: March 21 to June 21. Winter: June 21 to September 23. Spring: September 23 to December 21.

###### Electrolyte levels and renal function of patients not on acute dialysis at the time of laboratory testing.

                            **Survivors (n=95)**   **Non-survivors (n=22)**   *p*-value
  ------------------------ ---------------------- -------------------------- -----------
  Ca^++^ (mg/dL)              4.7 \[4.6-4.9\]          4.4 \[3.8-4.7\]          0.001
  GFR (mL/min/1.73 m^2^)        60 \[48-60\]             59 \[26-60\]           0.042
  Phosphorus (mg/dL)          2.9 \[2.3-4.2\]          3.2 \[2.7-4.3\]          0.334
  Magnesium (mg/dL)               2.0±0.4                  1.9±0.36             0.345

GFR: glomerular filtration rate calculated by the Modification of Diet in Renal Disease Study Group (MDRD). Values are expressed as the total mean ± 95% confidence interval OR the median \[interquartile range\].

###### Crude and adjusted mortality by Poisson regression.

                                       **Crude relative risk**   **95% CI**   **Adjusted relative risk**   **95% CI**
  ----------------------------------- ------------------------- ------------ ---------------------------- ------------
  Vitamin D (25\[OH\]D3 ≤ 12 ng/mL)             2.11             1.08-4.11               2.20              1.07-4.54
  APACHE II                                     1.06             1.03-1.09               1.03               0.99-1.8
  SOFA                                          1.11             1.06-1.17               1.04              0.97-1.11
  Lactate                                       1.17             1.07-1.17               1.04              0.99-1.10
  Albumin                                       0.58             0.38-0,88               0.75              0.47-1,19
  BMI                                           1.01             0.96-1.05               0.99              0.95-1.03
  Sepsis                                        1.00             0.63-1.58               1.06              0.54-2.07

APACHE II: Acute Physiology and Chronic Health Disease Classification System II; SOFA: Sequential Organ Failure Assessment; BMI: body mass index (Kg/m^2^); CI: confidence interval.

###### Mortality, mechanical ventilation and culture positivity according to vitamin D (25\[OH\]D3) status.

                                                                        **25\[OH\]D3 ≤ 12** **ng/mL**   **25\[OH\]D3 \> 12** **ng/mL**   *p*-value
  -------------------------------------------------------------------- ------------------------------- -------------------------------- -----------
  28-day mortality, %                                                               32.2                             13.2                  0.014
  Mechanical ventilation,%                                                          74.6                             77.4                  0.834
  Infections[\*](#tfn5-cln_70p326){ref-type="table-fn"}                             10.08                            8.98                  0.468
  Positive cultures[\*](#tfn5-cln_70p326){ref-type="table-fn"}                      13.95                           12.35                  0.369
  Positive blood cultures[\*](#tfn5-cln_70p326){ref-type="table-fn"}                3.86                             3.26                  0.516

ICU: Intensive Care Unit

\*Rate of infections per 100 patient-days in ICU
